Announcements Trials

Browse Landscape

Status

No longer available 1

Sponsor Class

Study Type

Interventional 242 Observational 18 Expanded_access 1

Sponsor

Cancer Type

Conditions

EGFR T790M Mutation Positive NSCLC 1

Interventions

3-Iodobenzylguanidine 9 Amifampridine 6 nilotinib 5 Magnetic Resonance Spectroscopy 5 Cyclophosphamide 5 trametinib 4 pembrolizumab 4 gallium 68 PSMA-11 4 fludarabine 4 elotuzumab 4 dabrafenib 4 Nivolumab 4 Bortezomib 4 Afatinib 4 venetoclax 3 regorafenib 3 midostaurin 3 fludarabine phosphate 3 TIC10 compound 3 Sunitinib 3 Prednisone 3 Lenalidomide 3 Ipilimumab 3 Everolimus 3 Dexamethasone 3 Crizotinib 3 Capecitabine 3 Axitinib 3 Alpelisib 3 Abiraterone Acetate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × osimertinib × Clear all

NCT02451852 2016-07-14

AZD9291 US Expanded Access Program

AstraZeneca

No longer available

EGFR T790M Mutation Positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡